{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T09:55:13Z","timestamp":1780566913458,"version":"3.54.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1038\/bmt.2014.269","type":"journal-article","created":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T18:19:02Z","timestamp":1417457942000},"page":"367-374","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Comparison of non-myeloablative conditioning regimens for lymphoproliferative disorders"],"prefix":"10.1038","volume":"50","author":[{"given":"S","family":"Hong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Le-Rademacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Artz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P L","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B R","family":"Logan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M C","family":"Pasquini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,12,1]]},"reference":[{"key":"BFbmt2014269_CR1","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.1182\/blood.V97.11.3390","volume":"97","author":"P McSweeney","year":"2001","unstructured":"McSweeney P, Niederwieser D, Schizuru J . Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390\u20133400.","journal-title":"Blood"},{"key":"BFbmt2014269_CR2","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1182\/blood-2003-02-0482","volume":"102","author":"MB Maris","year":"2003","unstructured":"Maris MB, Niederwieser D, Sandmaier BM, Storer B, Stuart M, Maloney D et al. HLA-matched unrelated donor hematopoieitc cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancie. Blood 2003; 102: 2021\u20132030.","journal-title":"Blood"},{"key":"BFbmt2014269_CR3","first-page":"384","volume":"16","author":"D Niederwieser","year":"2003","unstructured":"Niederwieser D, Maris M, Shizuru JA, Petersdorf E, Hegenbart U, Sandmaier BM et al. Low-dose TBI and fludarabine followed by HCT from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and MMF can induce durable complete chimerism and sustained remissions in patients with hematologic diseases. Blood 2003; 16: 384\u2013394.","journal-title":"Blood"},{"key":"BFbmt2014269_CR4","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1182\/blood.V89.8.3048","volume":"89","author":"R Storb","year":"1997","unstructured":"Storb R, Yu C, Wagner JL, Deeg HJ, Nash RA, Kiem HP et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 1997; 89: 3048\u20133054.","journal-title":"Blood"},{"key":"BFbmt2014269_CR5","unstructured":"Pasquini MC, Wang Z. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR summary slides 2013. Available at http:\/\/www.cibmtr.org."},{"key":"BFbmt2014269_CR6","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1200\/JCO.1998.16.8.2817","volume":"16","author":"IF Khouri","year":"1998","unstructured":"Khouri IF, Keating M, Korbling M, Przepiorka D, Anderlini P, O\u2019Brien S et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16: 2817\u20132824.","journal-title":"J Clin Oncol"},{"key":"BFbmt2014269_CR7","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1182\/blood-2004-04-1506","volume":"104","author":"F Baron","year":"2004","unstructured":"Baron F, Baker J, Storb R . Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 2004; 104: 2254\u20132262.","journal-title":"Blood"},{"key":"BFbmt2014269_CR8","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1182\/blood-2007-07-098483","volume":"111","author":"ML Sorror","year":"2008","unstructured":"Sorror ML, Storer BE, Maloney DG, Sandmaier BM, Martin PJ, Storb R . Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia. Blood 2008; 111: 446\u2013452.","journal-title":"Blood"},{"key":"BFbmt2014269_CR9","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.beha.2011.03.008","volume":"24","author":"IF Kouri","year":"2011","unstructured":"Kouri IF . Allogeneic stem cell transplantation in follicular lymphoma. Best Pract Res Clin Haematol 2011; 24: 271\u2013277.","journal-title":"Best Pract Res Clin Haematol"},{"key":"BFbmt2014269_CR10","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.bbmt.2005.10.006","volume":"12","author":"G Laport","year":"2005","unstructured":"Laport G . The role of hematopoietic cell transplantation for follicular non-Hodgkin\u2019s lymphoma. Biolo Blood Marrow Transplant 2005; 12: 59\u201365.","journal-title":"Biolo Blood Marrow Transplant"},{"key":"BFbmt2014269_CR11","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.blre.2006.01.001","volume":"20","author":"K Besien","year":"2006","unstructured":"Besien K . The evolving role of autologous and allogeneic stem cell transplantation in follicular lymphoma. Blood Rev 2006; 20: 235\u2013244.","journal-title":"Blood Rev"},{"key":"BFbmt2014269_CR12","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.transci.2007.04.008","volume":"37","author":"V Banerjii","year":"2007","unstructured":"Banerjii V, Johnston J, Seftel M . The role of hematopoietic stem cell transplantation in chronic lymphocytic leukemia. Transfus Apher Sci 2007; 37: 57\u201362.","journal-title":"Transfus Apher Sci"},{"key":"BFbmt2014269_CR13","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009; 15: 1628\u20131633.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2014269_CR14","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1177\/030089169908500503","volume":"85","author":"I Corazziari","year":"1999","unstructured":"Corazziari I, Mariotto A, Capocaccia R . Correcting the completeness bias of observed prevalence. Tumori 1999; 85: 370\u2013381.","journal-title":"Tumori"},{"key":"BFbmt2014269_CR15","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1002\/(SICI)1097-0258(19970228)16:4<425::AID-SIM414>3.0.CO;2-Z","volume":"16","author":"R Capocaccia","year":"1997","unstructured":"Capocaccia R, De Angelis R . Estimating the completeness of prevalence based on cancer registry data. Stat Med 1997; 16: 425\u2013440.","journal-title":"Stat Med"},{"key":"BFbmt2014269_CR16","first-page":"825","volume":"15","author":"D Przepiorka","year":"1995","unstructured":"Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825\u2013828.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2014269_CR17","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.bbmt.2010.07.015","volume":"17","author":"A Bashey","year":"2011","unstructured":"Bashey A, Owar K, Johnson JL, Edwards PS, Kelly M, Baxter-Lowe LA et al. Reduced-intensity conditioning allogeneic hematopoietic cell transplantation for patients with hematologic malignancies who relapse following autologous transplantation: a multi-institutional prospective study from the Cancer and Leukemia Group B. Biol Blood Marrow Transplant 2011; 17: 558\u2013565.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2014269_CR18","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.bbmt.2013.11.029","volume":"20","author":"CS Sauter","year":"2014","unstructured":"Sauter CS, Barker JN, Lechner L, Zheng J, Devline SM, Papdopoulos EB et al. A phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with B cell lymphoid malignancies: favorably durable event-free survival in chemosensitive patients. Biol Blood Marrow Transplant 2014; 20: 354\u2013360.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2014269_CR19","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/sj.bmt.1705027","volume":"36","author":"E Kusumi","year":"2005","unstructured":"Kusumi E, Kami M, Kanda Y, Murashige N, Kishi Y, Suzuki R et al. Reduced-intensity hematopoietic stem-cell transplantation for malignant lymphoma: a retrospective survey of 112 adult patients in Japan. Bone Marrow Transplant 2005; 36: 205\u2013213.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2014269_CR20","doi-asserted-by":"publisher","first-page":"5530","DOI":"10.1182\/blood-2008-01-136242","volume":"111","author":"IF Khouri","year":"2008","unstructured":"Khouri IF, McLaughlin P, Saliba RM, Hosing C, Korbling M, Lee MS et al. Eight year-experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning wiht fludarabine, cyclophosphamide, and rituximab. Blood 2008; 111: 5530\u20135336.","journal-title":"Blood"},{"key":"BFbmt2014269_CR21","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1097\/00007890-200102150-00017","volume":"71","author":"J Mattsson","year":"2001","unstructured":"Mattsson J, Uzunel M, Remberger M, Ringen O . T cell mixed chimerism is significantly correlated to a decreased risk of acute graft-versus-host disease after allogeneic stem cell transplantation. Transplantation 2001; 71: 433\u2013439.","journal-title":"Transplantation"},{"key":"BFbmt2014269_CR22","first-page":"767","volume":"18","author":"R Huss","year":"1996","unstructured":"Huss R, Deeg HJ, Gooley T, Bryant E, Leisenring W, Clift R et al. Effect of mixed chimerism on graft-versus-host disease, disease recurrence and survival after HLA-identical marrow transplantation for aplastic anemia or chronic myelogenous leukemia. Bone Marrow Transplant 1996; 18: 767\u2013776.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2014269_CR23","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/S0140-6736(98)11135-2","volume":"353","author":"M Sykes","year":"1999","unstructured":"Sykes M, Preffer F, McAfee S, Saidman SL, Weymouth D, Andrews DM et al. Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone marrow transplantation. Lancet 1999; 353: 1755\u20131759.","journal-title":"Lancet"},{"key":"BFbmt2014269_CR24","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.leukres.2013.12.012","volume":"38","author":"R Ram","year":"2013","unstructured":"Ram R, Yeschurun M, Vidal L, Shpilberg O, Gafter-Gvili A . Mycophenolate mofetil vs methotrexate for the prevention of graft-versus-host-disease\u2014systematic review and meta-analysis. Leuk Res 2013; 38: 352\u2013360.","journal-title":"Leuk Res"},{"key":"BFbmt2014269_CR25","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/bmt.2013.167","volume":"49","author":"GL Chen","year":"2014","unstructured":"Chen GL, Zhang T, Hahn Y, Abrams S, Ross M, Liu H et al. Acute GVHD prophylaxis with standard-dose, micro-dose. Bone Marrow Transplant 2014; 49: 248\u2013253.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2014269_CR26","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/bmt.2011.104","volume":"47","author":"L Johnston","year":"2012","unstructured":"Johnston L, Florek M, Armstrong R, McCune JS, Arai S, Brown J et al. Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation. Bone Marrow Transplant 2012; 47: 581\u2013588.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2014269_CR27","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.bbmt.2009.04.004","volume":"15","author":"W Sabry","year":"2009","unstructured":"Sabry W, Le Blanc R, Labbe AC, Sauvageau G, Couban S, Kiss T et al. Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality. Biol Blood Marrow Transplant 2009; 15: 919\u2013929.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2014269_CR28","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1016\/j.bbmt.2013.06.002","volume":"19","author":"B Kornblit","year":"2013","unstructured":"Kornblit B, Maloney DG, Storb R . Fludarabine and 2-Gy TBI is superior to 2 Gy TBI as conditioning for HLA-matched related hematopoietic cell transplantation: a phase III randomized trial. Biol Blood Marrow Transplant 2013; 19: 1340\u20131347.","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt2014269.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2014269","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2014269.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T18:05:02Z","timestamp":1648058702000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt2014269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,1]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["BFbmt2014269"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2014.269","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,1]]},"assertion":[{"value":"15 August 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2014","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2014","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2014","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}